ONC: Koefisien rega marang pendapatan BeiGene Ltd.
BeiGene Ltd is developing advanced oncology treatments through strategic partnerships and molecule licensing. The divergence of the P/S ratio from its historical average illustrates the market valuation, where the current level is 6.60. A global approach to clinical trials accelerates the launch of affordable drugs, yet strict government price controls and colossal R&D expenditures pose significant challenges to business margins.
Rincian analitis perusahaan BeiGene Corp (ONC)
- kuotasi saiki lan rata-rata prakiraan nilai:
- informasi kapitalisasi pasar:
- rincian nilai buku perusahaan:
- statistik kawajiban utang lan likuiditas:
Rasio Utang marang Ekuitas BeiGene Ltd|ONC - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal BeiGene Oncology|ONC - Gunggung utang perusahaan|Rasio utang marang aset resik BeiGene Corp|ONC - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan BeiGene|Rasio likuiditas perantara beigene.com
- rincian bathi lan kelipatan pasar:
ONC - Bathi resik|Prakiraan bathi resik BeiGene Ltd|ONC - Rasio rega marang bathi|Rasio prakiraan rega marang bathi BeiGene Ltd.|ONC - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan BeiGene Corp|ONC - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan BeiGene|ONC - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan beigene.com|ONC - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep BeiGene Ltd
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:beigene.com, ONC
Efficient international logistics and production diversification at BeiGene Ltd (ONC) ensure steady revenue growth, making the business valuation based on sales a key indicator of resilience. By analyzing the P/S multiple, an investor can see the ratio of market capitalization to sales volume, which helps determine the degree of overpayment for the asset and assess market expectations regarding the scaling of the company's operations.
Pesaing BeiGene Ltd
HALO - Rega marang dodolan|Multiplikator P/S RVMD (Revolution Medicines, Inc.)|Koefisien rega marang pendapatan Ascentage Pharma Group International (AAPG)|CG Oncology Corp - Multiplikator P/S|Multiplikator rega marang pendapatan UroGen Pharma Corp (URGN)|BCAX: Multiplikator P/S|Rega marang dodolan personalis.com (PSNL)|Rasio rega marang pendapatan Erasca|Rasio kapitalisasi marang pendapatan DCTH (Delcath Systems Inc)|Multiplikator P/S YMAB|AURA - Rega marang dodolan|Candel Therapeutics, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ARAY|SLS - Rasio rega marang pendapatan|ACTU: Rasio rega marang pendapatan|CTOR (Citius Oncology, Inc) - Kapitalisasi marang pendapatan|HURA: Kapitalisasi marang volume dodolan|TARA (Protara Therapeutics) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan FATE (fatetherapeutics.com)|Rasio rega marang pendapatan Aadi Bioscience Inc (WHWK)|TCRX - Rega marang dodolan|Rasio rega marang pendapatan Champions Oncology, Inc. CSBR|XBIT: Rasio kapitalisasi marang pendapatan|CEL-SCI Corp - Multiplikator P/S|ostherapies.com (OSTX) - Kapitalisasi marang pendapatan|RADX: Multiplikator P/S|Kapitalisasi marang pendapatan Artiva Biotherapeutics|ANL (Adlai Nortye Ltd) - Multiplikator P/S|Multiplikator P/S Veru Corporation|Rasio rega marang pendapatan Tempest Therapeutics (TPST)|xiliotx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S RENB (Renovaro)|MURA - Kapitalisasi marang pendapatan|Kairos Pharma Inc - Multiplikator P/S|Rega marang dodolan OnKure Therapeutics Inc|w2.cytomed.sg (GDTC) - Rasio rega marang pendapatan|Curis - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan APLM|THAR: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ADVB|Kapitalisasi marang pendapatan Genprex Inc GNPX|Calidi Biotherapeutics, Inc. - Kapitalisasi marang pendapatan|Multiplikator P/S sunshinebiopharma.com SBFM|XBIO - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan SLRX (Salarius Pharmaceuticals Inc)|PPBT: Multiplikator P/S|Rega marang dodolan American Oncology Network, Inc. (AONC)|BGNE (BeiGene, Ltd.) - Multiplikator P/S|Rasio rega marang pendapatan CKPT|Multiplikator P/S ELEV|ICAD - Rega marang dodolan|Multiplikator P/S IKNA (Ikena Oncology)|Koefisien rega marang pendapatan Notable Labs Corp (NTBL)|Viracta - Multiplikator P/S|Multiplikator rega marang pendapatan morphosys.com (MOR)|NAYA: Multiplikator P/S|Rega marang dodolan Ascentage Pharma Group International (AAPGV)
